Tvardi Therapeutics Inc.
TVRD | NASDAQ
$1.69
+$0.08 (+4.97%)
Sep 22, 2026, 2:19 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | -26.06M | -20.11M | -22.89M | -28.32M | -35.27M | -54.78M | -75.9M | -95.53M | -111.08M | -91.07M | -60.37M | -28.03M |
Depreciation & Amortization | 95K | 119K | 119K | 119K | 168K | 198K | 216K | 274K | 722K | 645K | 603K | 521K |
Stock-Based Compensation | 1.06M | 343K | 53K | -300K | -639K | 80K | 3.35M | 3.43M | 3.43M | 3.43M | 85K | n/a |
Other Working Capital | 1.51M | 2.04M | -1.74M | -438K | -4.32M | -1.48M | 6.03M | 8.17M | 13.01M | 10.63M | 6.54M | 1.87M |
Other Non-Cash Items | -1.63M | -9.96M | -4.71M | -2.62M | 6.37M | 21.87M | 18.16M | 20.91M | 15.15M | 9.79M | 8.05M | 3.23M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 1.51M | 4.94M | 927K | 5.48M | -6M | -6.31M | -7.53M | -3.24M | 11.96M | 9.82M | 14.7M | 4.64M |
Operating Cash Flow | -25.03M | -24.67M | -26.5M | -25.64M | -35.37M | -38.94M | -61.71M | -74.24M | -79.91M | -67.47M | -37.02M | -19.65M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | -210K | -1.05M | -3.1M | -3.42M | -3.21M | -2.38M | -323K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | -31.49M | -47.86M | -47.86M | -47.86M | 15.84M | n/a | -65M | -87.85M | -120.06M | -87.85M | -22.85M |
Sales Maturities Of Investments | 10.35M | 21.4M | 26.9M | 21.9M | 19.05M | 23.49M | 77M | 113.85M | 157.68M | 142.18M | 83.18M | 46.33M |
Other Investing Acitivies | 10.12M | 4.98M | n/a | n/a | n/a | -32.21M | -32.21M | -32.21M | -32.21M | n/a | n/a | n/a |
Investing Cash Flow | 20.47M | -5.11M | -20.97M | -25.97M | -28.82M | 6.91M | 43.74M | 13.54M | 34.19M | 18.9M | -7.05M | 23.16M |
Debt Repayment | n/a | -1.01M | -1.01M | 27.29M | 26.6M | 26.99M | 26.31M | 34.49M | 35.18M | 35.79M | 36.47M | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -429K | 22.17M | 20.57M | 19.28M | 19.71M | -2.9M | -1.29M | -5K | -5K | n/a | n/a | n/a |
Financial Cash Flow | -321K | 21.7M | 20.09M | 47.1M | 46.73M | 24.1M | 25.02M | 34.49M | 36.3M | 36.91M | 37.59M | 1.12M |
Net Cash Flow | -4.88M | -14.37M | -33.66M | -39.92M | -51.37M | -35.56M | -20.57M | -24.72M | -9.42M | -11.66M | -6.47M | 4.63M |
Free Cash Flow | -25.03M | -24.67M | -26.5M | -25.64M | -35.37M | -39.15M | -62.75M | -77.34M | -83.33M | -70.68M | -39.39M | -19.97M |
Adj. Free Cash Flow | -26.09M | -25.01M | -26.55M | -25.34M | -34.73M | -39.23M | -66.1M | -80.77M | -86.76M | -74.11M | -39.48M | -19.97M |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a | -210K | -1.05M | -3.1M | -3.42M | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -25.03M | -24.67M | -26.5M | -25.64M | -35.37M | -39.15M | -62.75M | -77.34M | -83.33M | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove TVRD